Most patients survive acute myocardial infarction (MI). Yet this encouraging development
has certain drawbacks: heart failure (HF) prevalence is increasing and patients affected tend …

The retraction of> 30 falsified studies by Anversa et al. has had a disheartening impact on
the cardiac cell therapeutics field. The premise of heart muscle regeneration by the …

Given the rising prevalence of cardiovascular disease worldwide and the limited therapeutic
options for severe heart failure, novel technologies that harness the regenerative capacity of …

In tissue engineering and regenerative medicine, stem cell—specifically, mesenchymal
stromal/stem cells (MSCs)—therapies have fallen short of their initial promise and hype. The …

Functional and perfusable vascular network formation is critical to ensure the long-term
survival and functionality of engineered tissues after their transplantation. Although several …

Cardiac diseases such as myocardial infarction and heart failure have been the leading
cause of death worldwide for more than 20 years, and new treatments continue to be …

Heart failure (HF) is one of the leading causes of death worldwide and has reached
epidemic proportions in most industrialized nations. Despite major improvements in the …

Myocardial infarction is the first cause of worldwide mortality, with an increasing incidence
also reported in developing countries. Over the past decades, preclinical research and …

Transplantations of various stem cells or their progeny have repeatedly improved cardiac
performance in animal models of myocardial injury; however, the benefits observed in …

Establishing an appropriate disease model that mimics the complexities of human
cardiovascular disease is critical for evaluating the clinical efficacy and translation success …